en · de · es · fr · pt
melanotan-2-notes.peptides9002.com › Guide › Storage, Verification And Regulatory Status — Explained

Storage, Verification And Regulatory Status — Explained

By Editorial Desk · published 2026-04-03 · last reviewed 2026-05-04 · Guide

Everything below concerns alpha-MSH analogue. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.

Last reviewed on 2026-05-04. Where a claim depends on a specific study, the study is described rather than over-claimed.

Storage, Verification and Regulatory Status

Identity and purity are usually assessed by reversed-phase high-performance liquid chromatography, which separates the target peptide from truncated or oxidised impurities. Mass spectrometry, most often coupled to liquid chromatography, confirms molecular mass and detects substitutions that chromatography alone may miss. Amino acid analysis and peptide mapping supply additional structural evidence, while nuclear magnetic resonance is reserved for full structural confirmation. Laboratories that examine samples sold online report wide variation in actual content, with some vials containing little or none of the labelled material.

Melanotan-2 appears on the World Anti-Doping Agency prohibited list within the peptide hormone class, and several national regulators treat it as an unapproved prescription substance. Some countries restrict importation or sale for personal use. Because the compound is widely traded as a research chemical, the practical legal picture differs between jurisdictions and shifts over time. Human safety data covering long periods are limited, and whether repeated pigmentation changes carry any lasting risk to melanocytes remains an open question.

Freeze-dried melanotan-2 is normally kept as a desiccated powder at minus twenty degrees Celsius or lower, shielded from light and moisture. Peptides of this size degrade through hydrolysis, oxidation and deamidation, and each pathway accelerates as temperature and water activity rise. Repeated freeze-thaw cycles promote aggregation and loss of material, so aliquoting a stock solution before freezing is standard laboratory practice. Once dissolved, the solution is markedly less stable than the powder. In laboratory work, solutions are generally refrigerated and used within days rather than kept for months.

Background and Mechanism of Melanotan-2

Early published reports described melanotan-2 as a tanning agent without sun protection, which means darkening is not the same as protection against ultraviolet radiation. Later studies explored the peptide in erectile dysfunction, hemorrhagic shock, and some skin conditions. No regulator in the United States or Europe has approved it for clinical use. Many products labelled melanotan-2 are sold without approval and their identity and purity are unverified. Its long-term safety in humans remains an open question.

Melanotan-2, also written Melanotan II, is a synthetic cyclic heptapeptide designed as an analogue of alpha-melanocyte-stimulating hormone. Its sequence is Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-NH2, and the lactam bridge between the aspartate and lysine side chains constrains the peptide into a ring. This structural change increases receptor affinity and metabolic stability relative to the native hormone. The compound was created in the 1980s as a research tool for studying pigmentation biology.

Melanotan-2 at a glance

PropertyValueNotes
Typical storage temperature-20 °C or belowFor the lyophilised powder, desiccated
Storage formSealed vial, protected from lightAmber glass or foil-wrapped containers
Reconstituted stabilityShort, refrigerateDegradation accelerates in solution
Typical analytical methodReversed-phase HPLC with mass spectrometryPurity assessment plus identity confirmation
Common synonymsMelanotan II, MT-IIAlso written melanotan-2

Regulatory Status and Analytical Detection

Identification in laboratories relies on reversed-phase liquid chromatography coupled with tandem mass spectrometry, with product-ion spectra compared against a certified reference standard. High-resolution mass spectrometry supplies accurate mass confirmation, and peptide mapping after enzymatic digestion separates melanotan II from closely related analogues. Quantitation of seized material is complicated by unknown counter-ions and residual trifluoroacetate left from purification. Immunoassays raised against alpha-melanocyte-stimulating hormone can cross-react, so chromatographic confirmation is normally required. Urinary detection windows are short, and reported limits of detection differ substantially between laboratories.

Melanotan II holds no marketing authorisation from the Food and Drug Administration, the European Medicines Agency, the UK Medicines and Healthcare products Regulatory Agency or Australia's Therapeutic Goods Administration. Products sold under that name are treated as unapproved new drugs, and their sale or import is prohibited in several jurisdictions. Other countries classify the peptide as a prescription-only medicine or place it among controlled substances, so the legal position changes with the destination market. No pharmacopoeial monograph supplies an official specification, because the material is not a licensed pharmaceutical. Consequently, products offered online are not manufactured to a shared public standard.

Related pages on this site

Peptide Identity and Structural Background

Structurally, Melanotan-2 retains the core recognition motif of alpha-melanocyte-stimulating hormone while adding a lactam bridge that links two side chains and constrains the molecule into a ring. This modification lowers susceptibility to enzymatic degradation. The compound acts as an agonist at melanocortin receptors, particularly subtypes associated with melanin production. Because the same receptor family influences several physiological processes, researchers note that its activity is not confined to pigmentation alone. Receptor selectivity continues to be examined in published studies.

Melanotan-2 is a synthetic cyclic heptapeptide designed as an analogue of alpha-melanocyte-stimulating hormone, a naturally occurring peptide involved in pigmentation signalling. Its sequence incorporates modified residues that increase potency and extend biological activity relative to the native hormone. The compound binds receptors of the melanocortin family and is examined mainly in laboratory research. It does not occur naturally and exists only as a manufactured chemical entity produced by solid-phase synthesis.

The peptide was developed during the 1980s by researchers investigating melanocortin signalling and skin pigmentation pathways. Early work focused on analogues of alpha-melanocyte-stimulating hormone that would resist enzymatic breakdown more effectively than the parent molecule. Melanotan-2 emerged from that programme as a shortened, cyclised variant. Reports describing its synthesis and receptor activity later appeared in the scientific literature. Commercial availability grew through unregulated channels rather than through pharmaceutical approval.

Handling, Storage and Analytical Verification

Identity and purity are assessed mainly by reversed-phase high-performance liquid chromatography with ultraviolet detection, often paired with mass spectrometry. Retention time supports identity, while the mass spectrum confirms the molecular weight of the intact peptide. Purity is frequently reported as a percentage of total peak area, a figure that depends on the wavelength, column and gradient used. Impurity profiling may also look for truncated sequences, oxidised forms and residual counterions. Amino acid analysis and peptide mapping provide orthogonal confirmation when required.

Regulatory status varies by jurisdiction, and the substance is frequently described as unapproved for therapeutic use. Some authorities classify it alongside prescription-only medicines or controlled categories, while others address it through general consumer protection rules. Analytical surveys have reported mismatches between label claims and measured content in products sold online, although the scope of such testing is limited. Whether these discrepancies are widespread remains an open question. Discussion in the literature therefore tends to combine chemistry, supply-chain observation and policy analysis.

The material is commonly handled as a lyophilized powder in sealed vials. The solid dissolves readily in water and in polar organic solvents, producing a clear solution after reconstitution. Light, heat and repeated freeze-thaw cycles are the concerns most often raised in handling guidance, because peptide bonds and the constrained ring can degrade. Working solutions are generally prepared fresh, and material left in solution is treated as less stable than the dry form. These properties shape how laboratories store and aliquot reference material.

Melanotan-2 Structure and Receptor Pharmacology

Melanotan-2 is a synthetic cyclic heptapeptide designed as a structural analogue of alpha-melanocyte-stimulating hormone, the endogenous tridecapeptide that regulates pigment production. Two modifications distinguish it from the natural hormone: norleucine replaces methionine at the N-terminus, which limits oxidation, and a D-phenylalanine substitution raises receptor affinity. The ring is closed through an aspartate-lysine lactam bridge, giving the molecule a constrained conformation. The free base has a molecular mass near 1024 daltons, and commercial material is usually supplied as an acetate salt. It appears in the literature as a research peptide rather than an approved therapeutic agent.

Receptor studies place melanotan-2 among non-selective melanocortin agonists, binding MC1R, MC3R, MC4R and MC5R rather than a single subtype. Activation of MC1R on cutaneous melanocytes raises tyrosinase activity and shifts pigment synthesis toward eumelanin, which is darker and more photostable than pheomelanin. Central receptors, particularly MC4R, are associated with appetite suppression and with reported effects on sexual function. Because subtype selectivity is low, the same molecule engages pigment, metabolic and vascular pathways at once, and this breadth is a common explanation offered for the range of adverse events described in user reports.

Supporting material

=== Philippines === The Armed Forces of the Philippines formerly had a combat ration similar to American MREs. Typically, they included a small can of sardines or tuna, instant noodles, crackers, instant coffee, a small packet of peanuts, ginger tea, and a biscuit or cookie. Chocolate manufactured for hot conditions are sometimes issued. Canned rice is also issued. In 2016, "Ready-to-Eat" rations were announced to replace older rations. They are packed in green plastic retort pouches and considered fit to eat for Muslim service members (halal). For example, Menu #2 has four packs of cooked rice, one tuna rice with sisig, one pack of chicken sausage with sauce, one pack of chicken lechon paksiw, one pack of powdered milk, one pack of 3-in-1 coffee, one pack of plain crackers, a spork, and wet tissues.

Natural freshwater diatomaceous earth is preferred by many researchers over chromic oxide, which has been widely used for the same purpose, the latter being a known carcinogen and, therefore, a potential hazard to research personnel.

== Family and personal life == Dan Ariely was born to Yoram and Dafna Ariely in New York City while his father was studying for an MBA at Columbia University. He has two younger sisters. The family emigrated to Israel when he was three years old. He grew up in Ramat Hasharon. In his senior year of high school, Ariely was active in Hanoar Haoved Vehalomed, an Israeli youth movement affiliated with the Labor Zionist movement. While he was preparing a ktovet esh (fire inscription) for a traditional nighttime ceremony, the flammable materials he was mixing exploded, causing third-degree burns to over 70 percent of his body. In his writings entitled "Painful Lessons", Ariely described his hospitalization and treatments, detailing how that experience led to his research on "how to better deliver painful and unavoidable treatments to patients". Ariely was previously married to Sumedha (Sumi) Gupta in 1998; they have two children. After a second manuscript of his was retracted for containing fabricated data, it was reported that Ariely is seeking political office under the banner of the Pirate Party of Israel.

== Research and pipeline == In 2025, Novo tested whether semaglutide helped slow progression for Alzheimer's disease. However, on November 24, 2025, the company announced that the studies failed to find any effect of the drug on cognition and functioning in people with mild cognitive impairment or with dementia. Novo was researching pulmonary delivery systems for diabetic medications, and in the early stages of research into autoimmune and chronic inflammatory diseases, using technologies such as translational immunology and monoclonal antibodies. In September 2014, the company announced a decision to discontinue all research in inflammatory disorders, including the discontinuation of R&D in anti-IL-20 for the treatment of rheumatoid arthritis. In September 2018, it was reported that the company would lay off 400 administrative staff, laboratory technicians and scientists, in Denmark and China in order to concentrate research and development efforts on "transformational biological and technological innovation".

== E == efficacy – empirical – encephalitis – end-stage disease – endemic – endogenous – endoscopy – endotoxin – endpoint – enteric – enteritis – entry inhibitors – Env – envelope – enzyme – enzyme-linked immunosorbent assay (ELISA) – eosinophil – eosinophilic folliculitis – epidemic – epidemiological surveillance – epidemiology – epithelium – epitope – Epstein-Barr virus (EBV) – erythema – erythema multiforme – erythrocytes – etiology – exogenous – exotoxin – expanded access – experimental drug – expression system

Sources: en.wikipedia.org

Notes from published material

== Future development == Postmenopausal women may also suffer from HSDD due to a decline in androgen production from menopause. A research proposed two combinations of drugs, each designed against the different causes of HSDD. One combination is to utilise sublingual testosterone with a 5-HT1A receptor agonist to raise motivation for sex, by lifting the inhibition mechanisms in the brain's prefrontal regions. Testosterone is also proposed to be coupled with the PDE5 inhibitor, targeting an insensitive system for the production of sexual desire. As both clinical trials showed desirable results, this indicates the prosperity of further developing a single drug targeting HSDD for all women of different status, even though the FDA has not approved the two combinations.

The longest dictionary word, according to Kamus Besar Bahasa Indonesia, is heksakosioiheksekontaheksafobia, a 31-letter-long word meaning "hexakosioihexekontahexaphobia" or "the phobia of the number 666" in English. while the longest non-scientific word in the dictionary is mentransmigrasilokalkan, which is 23 letters long, meaning "conducting transmigration within the boundaries of a single region or area" in English.

Similarly, thermostable proteins are rich in salt bridges or/and extra disulfide bridges stabilizing the structure. Other factors of protein thermostability are compactness of protein structure, oligomerization, and strength interaction between subunits.

Psilocin (4-HO-DMT) is a close positional isomer of bufotenin (5-HO-DMT), which shows peripheral selectivity, and might be expected to have similarly restricted lipophilicity and blood–brain barrier permeability. But psilocin appears to form a tricyclic pseudo-ring system wherein its hydroxyl group and amine interact through hydrogen bonding. This in turn makes psilocin much less polar, more lipophilic, and more able to cross the blood–brain barrier and exert central actions than it would be otherwise. It may also protect psilocin from metabolism by monoamine oxidase (MAO). In contrast, bufotenin is not able to achieve this pseudo-ring system. Accordingly, bufotenin is less lipophilic than psilocin in terms of partition coefficient. But bufotenin does still show significant central permeability and, like psilocybin, can produce robust hallucinogenic effects in humans.

Similarly in the United States, the window of administration used to be 3 hours from onset of symptoms, but the newer guidelines also recommend use up to 4.5 hours after symptom onset, depending on the patient's presentation, past medical history, current comorbidities and medication usage. tPA appears to show benefit not only for large artery occlusions but also for lacunar strokes. Since tPA dissolves blood clots, there is risk of hemorrhage with its use.

Sources: en.wikipedia.org

Frequently asked questions

How should the powder be stored?

The lyophilised solid is best kept cold, dry and dark, typically at minus twenty degrees Celsius. Moisture and repeated warming cycles are the main causes of degradation. Solutions prepared from the powder are less stable and are normally used quickly.

Which analytical methods confirm identity?

Reversed-phase liquid chromatography assesses purity, while mass spectrometry confirms molecular mass and detects sequence errors. Amino acid analysis and peptide mapping add structural detail. These techniques are complementary rather than interchangeable.

What is its status in sport and medicines?

It is listed as a prohibited peptide hormone by the World Anti-Doping Agency. No medicines regulator has approved it for human use. Import and sale rules vary by country.

Is melanotan-2 a natural hormone?

No. It is a laboratory-made peptide, while the natural hormone is alpha-melanocyte-stimulating hormone, a longer peptide produced by the pituitary gland and by skin cells. Melanotan-2 mimics only a short active region of that hormone and contains non-natural residues such as D-phenylalanine.

Network